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Objectives:
 
 The complications of diabetes have the po-
tential to greatly impact the health-related quality of
life (HRQOL) of patients with type 2 diabetes. The ef-
fect of diabetic complications on HRQOL was assessed
in 1233 patients with type 2 diabetes who were not us-
ing insulin.
 
Methods and data: 
 
Patients were aged 35 and older and
had stable fasting serum glucose (FSG) after washout of
antidiabetic therapy. Patients who required insulin or
suffered from severe cardiovascular or hepatic disease,
 
neuropathy, or retinopathy were excluded. Patients com-
pleted the SF-36 generic quality of life questionnaire. De-
mographic data, including body mass index (BMI), blood
 
glucose hemoglobin A1c (HbA
 
1c
 
), FSG, and the presence
and severity of eight specified diabetic complications
were also collected. A linear regression analysis was per-
formed for each of the SF-36 domains and for the physi-
cal and mental health summary scales.
 
Results:
 
 The most prevalent diabetic complications were
hypertension (46% of patients), peripheral sensory neu-
ropathy (PSN; 12%), coronary artery disease (CAD;
8%), retinopathy (8%), and peripheral vascular disease
(PVD; 7%). Most (73%) of the complications were as-
sessed to be mild. PSN was associated with significantly
lower scores (i.e., worse quality of life) in the mental
health scale; CAD was associated with significant reduc-
tions of all but role-emotional and mental health scales
of the SF-36; and PVD was associated with significantly
lower physical and social functioning scales. Hyperten-
sion did not have an independent effect on HRQOL.
 
Conclusions:
 
 The presence of even mild diabetic com-
plications has a significant impact on patients’ quality
of life. Early diagnosis and treatment is essential to help
prevent deterioration of HRQOL in these patients.
 
Keywords:
 
 diabetic complications, quality of life, regres-
sion analysis, SF-36, type 2 diabetes.
 
Introduction
 
Type 2 diabetes is a considerable and evolving health-
care challenge in the Western world and in develop-
ing nations, primarily because of increased obesity,
aging populations, and more sedentary lifestyles.
It has been estimated that by 2010 approximately
250 million people worldwide will suffer from type
2 diabetes [1]. Complications associated with dia-
betes are a major cause of morbidity, mortality,
and health-care costs. The cost of treating these
complications in the United Kingdom in 2000 has
been estimated at approximately £2 billion, or 4%
of the total National Health Service budget [2].
With the estimated increase in newly diagnosed di-
abetes, the burden of both complications and cost
will continue to be significant. Complications of
diabetes can be divided into two categories: micro-
vascular complications, which include neuropathy,
retinopathy and nephropathy; and macrovascular
disease, which can result in stroke, coronary ar-
tery disease (CAD), and peripheral vascular dis-
ease (PVD).
Much of the morbidity and mortality associ-
ated with Type 2 diabetes is caused by complica-
tions associated with the disease. For example, di-
abetic retinopathy resulting in loss of vision is the
leading cause of blindness in working-aged per-
sons in the United States [3]. Of particular concern
in type 2 diabetes are the macrovascular effects
that give rise to cardiac, cerebrovascular, and pe-
ripheral vascular dysfunction. The American Dia-
betic Association has estimated that 75% to 80%
of adult diabetic patients will ultimately die as a
result of macrovascular complications due to their
underlying disease [4].
The diabetic complications described above not
only result in physical disability and cost, but also
lead to compromised health-related quality of life
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(HRQOL) [5]. The incidence (presence and num-
ber) of diabetic complications has been shown to
have a significant impact on quality of life in a
number of studies [6–9]. Individual studies have
found that reduced quality of life is associated with
diabetic neuropathy [10,11] and retinopathy [9]
and with diabetic foot [12,13]. Recent findings us-
ing the SF-20 have shown that cardiovascular dis-
ease is an independently contributing factor to the
reduction of quality of life in older-onset diabetes
[14] and have demonstrated a link between im-
paired quality of life and congestive heart disease
(CHD) and other macrovascular diseases [15].
The effect of glycemic control on quality of life
in the short term remains controversial. Several stud-
ies found little direct relation between glycemic
control and HRQOL using a number of measures
[7,8,16,17], as confirmed in a small study in Pima
Indians using the SF-36 [18]. Direct relationships
have been found between blood glucose and qual-
ity of life in severely hyperglycemic individuals
with either type 1 or type 2 diabetes [10,19].
However, long-term complications, particularly
microvascular disease, have been directly related
to poor glycemic control [20]. Because many pa-
tients are likely to remain undiagnosed for several
years before symptoms appear, many will show
evidence of diabetic complications at diagnosis
[21,22]. Patients with elevated blood glucose have
an increased risk of numerous microvascular and
macrovascular complications, all of which may
negatively affect HRQOL.
The present study used baseline assessments of
patients who participated in three different clinical
trials, the results of which have been presented
elsewhere [23–25]. In addition to standard clinical
measures, the impact of long-term diabetic com-
plications on HRQOL was assessed and is re-
ported in this paper.
 
Methods
 
Patients
 
Baseline data from a total of 1233 patients from
three clinical trials in type 2 diabetes were pooled.
Entry criteria for these studies required that patients
be over 35 years of age and receiving treatment for
their diabetes in the form of dietary modifications
alone or in combination with oral antidiabetic
agents. One study (study A) was conducted in pa-
tients aged 65 years or older. Existing therapy was
withdrawn and patients had stable fasting serum
glucose (FSG) levels during a washout period
prior to the baseline assessment. Severely hyper-
glycemic patients or those using insulin were not
eligible to participate. Also excluded were patients
suffering from severe neuropathy, severe CAD, and
moderate or severe nephropathy. The definitions
of mild, moderate, and severe diabetic complica-
tions used in all three studies are shown in Table 1.
All eligible patients enrolled in these studies were
included in the current analysis, provided they had
completed an HRQOL questionnaire on entering
the study and that sufficient demographic and
clinical data were available.
The data from all three studies were pooled to
give a sufficient number for statistical analysis. In-
terpatient variability in demographics, FSG, and
hemoglobin A
 
1c
 
 (HbA
 
1c
 
) were explicitly addressed
in the analysis. In addition, “study” was retained
as an explanatory factor in all regressions to cor-
rect for unobserved differences in patient popula-
tions. Patients were recruited from a total of 12
European countries.
 
Assessments
 
On entry, patients attended a clinic visit at which
time data were recorded by an investigator or
clinic nurse using an approved protocol and case
record form. Patient demographics including age,
sex, and ethnic origin were recorded. Diabetic
complications were recorded as absent, mild, moder-
ate, or severe, using the criteria shown in Table 1.
Complications assessed were retinopathy, periph-
eral sensory neuropathy (PSN), autonomic neu-
ropathy, diabetic foot, nephropathy, hypertension,
PVD, and CAD. Both FSG and HbA
 
1c
 
 were re-
corded, and patients completed the SF-36 quality-
of-life instrument (standard version) at the clinic
visit before receiving results of any tests or investi-
gations.
 
Quality-of-Life Instrument
 
The SF-36 is a 36-item, self-completed question-
naire with items divided into eight domains mea-
suring physical functioning, impairment to role
activities due to physical problems (role-physical),
impairment to role activities due to emotional
problems (role-emotional), social functioning, bodily
pain, mental health, vitality, and general health
perception. Another item, health transition, con-
siders changes in health over the preceding year.
Each domain is subsequently computed in terms
of a score from zero (poorest well-being) to 100
(highest well-being). Summary scores on two sub-
scales, the Physical Component score (PCS) and
Mental Component score (MCS), can also be cal-
culated [5]. The SF-36 has been validated in all the
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languages used in these studies. Individual scale
scores were calculated using the standard scoring
from the SF-36 users’ manual [5]. Scale scores
were deemed to be missing if more than half the
individual items were missing. If up to half the
items in a scale were missing, the mean of the
items present for that scale was used [5]. Aggre-
gate component scores were only calculated if all
eight component scores were available.
 
Statistical Methods
 
A general linear model was fitted using each SF-36
domain with the physical and mental health sum-
mary scales as dependent variables. The following
explanatory factors were included in the model:
gender, ethnic origin, and country; and presence
and severity of each of the eight diabetic complica-
tions, including age, BMI, duration of diabetes,
FSG and HbA
 
1c
 
. To ensure consistency of models
across the SF36 domains, all explanatory factors
were retained in the model. Factors were consid-
ered to be statistically significant if the proportion
of the variation (overall sum of squares) of the de-
pendent variable that the factor explained was sig-
nificantly greater than zero using an 
 
F
 
-test. Type II
sums of squares and significance were assessed at
 
p
 
 
 

 
 .05, two-sided test.
Separate analyses based on the logistic and un-
transformed data were performed; plots of stan-
dardized residuals against predicted values and
variables such as age and BMI showed that residu-
als from the untransformed data were randomly
distributed. The untransformed data reported here
performed adequately with regard to values out-
side the range.
To explore the validity of pooling the studies,
an analysis of variance was also performed on
each of the components to compare the between-
trial variability with the within-trial variability. Of
the eight component scores, role-emotional (
 
p
 
 
 

 
.5), body pain (
 
p
 
 
 

 
 .429), and vitality (
 
p
 
 
 

 
 .146)
showed no evidence of appreciable heterogeneity.
The other five scores and the two aggregate scores
exhibited significant heterogeneity (
 
p
 
 
 

 
 .001 for
all). We do not believe that this invalidates pool-
ing the data from the three studies because the dif-
ferences may be due in part to differences in age
and/or sex, or other population differences. To al-
low for remaining unobserved variation, we in-
cluded “study” as a random effect in each model.
 
Table 1
 
Classification of diabetic symptoms
 
Symptom Mild Moderate Severe
Diabetic retinopathy Nonproliferative: Preproliferative: Proliferative:
Venous dilation Cottom-wool spots Neovascularization
Microaneurysms Venous abnormalities Fibrous tissue
Small hemorrhages Arterial abnormalities Hemorrhage
Hard exudates Retinal detachment
Maculopathy
PSN Reduced vibration sensation 
to ankle 
Reduced sensation to pinprick
Absent tendon reflexes
Absent sensation to pinprick
Marked sensory loss in whole leg or 
foot, with or without pain
Autonomic neuropathy Loss of beat variation
Sweating 
Facial flushing
Genitourinary problems of no 
other origin 
Postural hypotension 
 

 
20 mmHg 
systolic BP
Cardiac arrhythmia of autonomic 
origin 
Regular urinary or fecal incontinence
Diabetic foot Cold 
Reduced but palpable pulses
Medical history includes ulceration 
Absent pulses
Gangrenous 
Amputation (for nontraumatic reason)
Nephropathy
Albuminuria Micro, 30–300mg/day Macro, 
 

 
300mg/day Macro, 
 

 
300 mg/day
Creatinine 180–200
 

 
mol/l Plasma 201–250 
 

 
mol/l 
 

 
250 
 

 
mol/l, nephrotoxic syndrome
Hypertension (untreated)
Diastolic BP, supine: 85 mmHg
 
  
 
BP
 
  
 
95 mmHg
 

 
95 mmHg
 

 
100 mmHg
Other: Systolic BP
 
  
 
160 mmHg Eye fundus changes Eye fundus changes
Grade III Grade III and IV
PVD Reduced lower limb pulses
Intermittent claudication
Rest pain 
Absent pulses
Absent pulses 
Ischemia/necrosis 
Surgery/amputation
CAD
Angina: On strenuous exercise Limits ordinary activities Angina at rest
Previous MI: One More than one
NYHA heart failure: Grade III Grade III or IV
 
BP, blood pressure; CAD, coronary artery disease; MI, myocardial infarction; NYHA, New York Heart Association; PSN, peripheral sensory neuropathy; PVD,
peripheral vascular disease. 
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To examine how the data compared with popu-
lation norms, the mean values for each SF-36 do-
main from this study were compared to two refer-
ence populations: 1) the general US population
aged 55–64 from the original Medical Outcome
Survey (MOS) [5]; and 2) the subgroup of non-
insulin dependent diabetes mellitus (NIDDM) from
the MOS [5].
The software used was SAS V6.12 (The SAS In-
stitute Inc., Cary, NC), and least square means
were calculated using the generalized linear model
(GLM) procedure.
 
Results
 
Patients
 
A total of 1233 patients were included from three
studies as follows: study A (110 patients); study B
(368 patients); and study C (755 patients). Patient
demographics are shown in Table 2. More men
than women were included in studies B and C,
while more women than men were included in
study A. Overall, 58% of patients were male. Al-
most all patients (98%) were white. The mean du-
ration of diabetes was 70 months (SD 
 

 
 69
months), the mean FSG was 11.1 mmol/L (SD 
 

 
3.1 mmol/L), and the mean HbA
 
1
 
c
 
1c
 
 was 8.0%
(SD 
 

 
 1.4%).
The most prevalent diabetic complications (Ta-
ble 3) were: hypertension (46% patients), PSN
(12%), CAD (8%), and PVD (7%). Other compli-
cations assessed were found in 3% or less of pa-
tients. Most of the complications were assessed to
be mild (73%), and the remaining were moderate
(22%) and severe (5%).
 
Health-Related Quality of Life
 
HRQOL scores for the combined population are
compared with the two reference populations in
Figure 1. Patients in this survey had better physi-
cal functioning, role-physical, pain, general health,
and vitality scores than patients with type 2 diabe-
tes surveyed in the MOS during the development
of the SF-36 [5]. Scores for mental health, social
functioning, and role-emotional scales, however,
were comparable to these reference scores (Figure
1). Although there was generally a wide variability
in scores for each domain (range: 0–100 for each
domain), the median score for role-physical, role-
emotional, and social functioning was 100, indi-
cating a substantial ceiling effect for these do-
mains. The mean PCS for the pooled population was
46.6 (SD 
 

 
 9.2, range 12.1–65.3), and the mean
MCS was 50.9 (SD 
 

 
 10.1, range 12.0–70.2).
 
Regression Analysis
 
The number of patients with severe complications
was small (
 

 
 10) for all conditions assessed apart
from hypertension. To increase numbers, patients
assessed as having a severe complication were
pooled with those having moderate complications
for each of the eight complications assessed in Ta-
ble 3. Only two patients were assessed as having
moderate diabetic foot, and these patients were
pooled with patients assessed as having mild dia-
betic foot for the same reason.
Several significant factors were identified in the
regression analysis. Sex, age, BMI, and country
were significant variables for most SF-36 domains.
Men consistently produced higher mean scores than
women. Several diabetic complications were iden-
tified as significant factors for the SF-36 domains
(Table 4). These included: CAD (significant for
the majority of the SF-36 domains); PVD (a signif-
icant determinant of physical and social function-
ing); PSN (a significant determinant of mental health
and the aggregate mental component); autonomic
neuropathy; and diabetic foot. In general, HRQOL
scores tended to decrease, indicating poorer quality
of life, in patients with more severe symptoms.
The duration of diabetes was not a significant
factor in any of the SF-36 domains, nor were hy-
pertension, retinopathy, or nephropathy. Glyce-
mic control, as measured by either FSG or HbA
 
1C
 
,
had little apparent impact on HRQOL.
 
Table 2
 
Summary of demographic and clinical 
characteristics for evaluable patients
 
Study A Study B Study C All patients
Characteristic (n 
 

 
 110) (n 
 

 
 368) (n
 

 
 755) (n 
 

 
 1233)
Gender
Male 51 210 448 709
Female 59 158 307 524
White 
(% patients)
96.4 94.8 99.3 97.7
Age (years)
Mean 
 

 
 SD 75 
 

 
 4.3 58 
 

 
 9.0 60 
 

 
 10.8 61 
 

 
 10.8
Interquartile 
range
72–77 52–65 52–68 53–70
BMI (kg/m
 
2
 
)
Mean 
 

 
 SD 26.5 
 

 
 3.8 29.4 
 

 
 5.1 29.0 
 

 
 4.8 28.9 
 

 
 4.9
Duration of diabe-
tes (months)
Mean 
 

 
 SD 127 
 

 
 105 72 
 

 
 70 60 
 

 
 57 70 
 

 
 69
FSG (mmol/L)
Mean 
 

 
 SD 11.3 
 

 
 3.8 11.7 
 

 
 3.3 10.8 
 

 
 2.7 11.1 
 

 
 3.1
HbA
 
1c
 
 (%)
Mean 
 

 
 SD 8.0 
 

 
 1.3 8.1 
 

 
 1.6 7.9 
 

 
 1.4 8.0 
 

 
 1.4
 
SD, standard deviation; BMI, body mass index; FSG, fasting serum glucose.
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Discussion
 
Results from this study indicate that even mild
complications in patients with type 2 diabetes can
have a profound effect on the patients’ perceived
HRQOL as measured using the well-validated and
widely used SF-36 questionnaire.
The present study excluded patients with the
most severe form of the disease, and consequently,
the greatest number of complications. The major-
ity of complications that occurred in the study
population were assessed as being mild. Because
many patients did not experience symptomatic
complications, mean SF-36 scores tended to be
high. Mean physical functioning, role-physical,
and general health perception scores were closer
to those of the US norm reference population than
to scores calculated in the MOS study for patients
with type 2 diabetes [5]. Scores for this patient
group were also higher than those generated by
Weinberger et al. [16] for a type 2 diabetes popu-
 
Table 3
 
Incidence of diabetic complications*
 
Study population Study A Study B Study C All patients
Complication Severity (n 
 

 
 110) (n 
 

 
 368) (n 
 

 
 755) (n 
 

 
 1233)
Hypertension 55 (50%) 157 (43%) 356 (47%) 568 (46%)
Mild 55 101 201 357
Moderate 0 54 117 171
Severe 0 2 38 40
PSN 8 (7%) 48 (13%) 92 (12%) 148 (12%)
Mild 6 40 81 127
Moderate 2 8 10 20
Severe 0 0 1 1
CAD 19 (17%) 10 (3%) 66 (9%) 95 (8%)
Mild 19 10 55 84
Moderate 0 0 11 11
Severe 0 0 0 0
Retinopathy 11 (10%) 37 (10%) 46 (6%) 94 (8%)
Mild 9 28 39 76
Moderate 2 5 5 12
Severe 0 4 2 6
PVD 11 (10%) 35 (10%) 37 (5%) 83 (7%)
Mild 11 23 32 66
Moderate 0 9 2 11
Severe 0 3 3 6
Nephropathy 3 (3%) 14 (4%) 16 (2%) 33 (3%)
Mild 3 14 15 32
Moderate 0 0 1 1
Severe 0 0 0 0
Autonomic neuropathy 0 (0%) 19 (5%) 5 (1%) 24 (2%)
Mild 0 9 4 13
Moderate 0 9 1 10
Severe 0 1 0 1
Diabetic foot 2 (2%) 4 (1%) 17 (2%) 23 (2%)
Mild 2 4 15 21
Moderate 0 0 2 2
Severe 0 0 0 0
 
 PSN, peripheral sensory neuropathy; CAD, coronary artery disease; PVD, peripheral vascular disease.
Figure 1 SF-36 scale scores: comparison with published
norms.
* Norms for US general population aged 55–64, n  269. See
Table 10.2, Ware et al. [5]
† Norms for type 2 diabetes population (also from US), n 
541, See Table 10.7, Ware et al. [5]
‡ Mean age 61.0 years, n  1233.
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lation, although the latter were older than our
population and had a longer mean duration of di-
abetes (10.3 vs. 5.7 years), suggesting a higher rate
of diabetic complications.
The regression analysis of a number of potential
contributing factors on HRQOL was studied. Age
and sex were consistently associated with HRQOL.
Lower HRQOL scores were associated with lower
age, whereas consistently higher scores were re-
ported by men. Duration of diabetes had no appar-
ent impact on HRQOL, while FSG and HbA1c were
the only significant covariates in isolated domains.
In the vitality domain, for example, average scores
decreased with elevated blood glucose levels, al-
though the converse was observed for HbA1c. Re-
sults from the United Kingdom Prospective
Diabetes Study (UKPDS) indicate that the HRQOL
of patients with type 2 diabetes is not affected by
intensive interventions aimed at improving blood
glucose control. However, patients who had hy-
poglycemic events during the study had more mood
disturbance and tension and reduced work satisfac-
tion [26].
Inclusion of complications as factors affecting
HRQOL demonstrated that HRQOL impairment
was most prevalent among patients with these dia-
betic complications. That many patients have
complications at the time of diagnosis, some of
which cannot be treated, suggests that significant,
potentially irreversible impairment of HRQOL
may already have occurred in a number of pa-
tients at the time of presentation. In the present
population, CAD was the factor most frequently
associated with a significant reduction in HRQOL,
affecting the physical domains in particular. With
early intervention, however, many diabetic com-
plications can be prevented. Research has shown
that treatment of the risk factors associated with
macrovascular disease is effective in type 2 diabe-
tes and that the occurrence of CAD can be re-
duced if patients are diagnosed before complica-
tions develop [27,28]. Furthermore, significant
associations with specific domains of the SF-36 re-
flected the facets of patients’ lifestyle affected by
other diabetic complications. For example, Table
4 shows a significant association between PVD
and the physical functioning domain.
Hypertension was not a significant factor in any
of the SF-36 domains, a not altogether surprising
finding since hypertension is asymptomatic in the
majority of patients. Treatment of hypertension is
nonetheless very important in this patient group.
Results from the recent UKPDS study have shown
that intensive treatment of hypertension in type 2
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diabetes decreases the risk of macrovascular and
microvascular complications [29] without affecting
HRQOL [26]. Similarly, there was no association
between mild retinopathy and HRQOL, although
it is expected that severe disease would impact on
HRQOL. Impaired visual acuity in patients with
type 2 diabetes has been associated with reduced
HRQOL as measured by the SF-20 [15].
The findings relating HRQOL to blood glucose
were ambiguous, as would be expected in a popula-
tion with a mean FSG of 11.1 mmol/l [7,8,16,17].
The impact of blood glucose on HRQOL appears
to be due to its important role in the development
of diabetic complications. Drug effects were not
evaluated in this study, because none of the pa-
tients was receiving drug therapy at the time of as-
sessment and all had completed a drug therapy
washout period of at least three weeks prior to the
baseline assessment.
This study used the SF-36 to assess HRQOL.
The advantages of this instrument are that it is
short and easily completed by the patient, is com-
prehensive, and is supported by a wealth of refer-
ence data, allowing for comparison between the
study population and reference populations. One
disadvantage of using a generic instrument such as
the SF-36 in a specific disease or condition is its
potential lack of sensitivity. Small changes in
HRQOL may be more easily detected using a dis-
ease-specific instrument such as the diabetes care
profile. That we were able to demonstrate differ-
ences in quality of life in this study using the
SF-36, a potentially insensitive instrument, sug-
gests that the impact of these complications on
quality of life is substantial.
Even though this sample of more than 1200
patients was large, some complications occurred
only in a small number of patients, and hence, re-
sults for patients with nephropathy, autonomic
neuropathy, and diabetic foot should be inter-
preted with caution. Research into more severely
disabled patients would be needed to clarify the
impact of these complications on HRQOL.
A limitation of this study was the need to pool
three separate patient populations to generate a
sufficiently large number for analysis. Heterogene-
ity between studies was detected, and was retained
as a random effect in the models to allow for un-
observed variation between populations. How-
ever, the differences observed between the studies
casts some doubt on the general applicability of
the final results.
It is interesting to note that CAD was the most
frequent complication significantly associated with
various SF-36 domains, which indicates that this
complication has a profound effect on quality of
life. Concomitant hypertension and dyslipidemia
may contribute to this macrovascular complica-
tion in diabetic patients [27], along with hyperin-
sulinemia [28]. Thus, while the principal aim of
long-term treatment is to improve glycemic con-
trol, alleviation of these cardiovascular risk fac-
tors is also of importance, both clinically and in
terms of improving patients’ quality of life.
Conclusion
This study has shown that diabetic complications,
particularly CAD, have a profound effect on the
HRQOL of patients with type 2 diabetes. Even the
presence of mild diabetic complications has a sig-
nificant impact on HRQOL, while biochemical
markers of the disease did not appear to directly
affect HRQOL. To improve HRQOL in patients
with type 2 diabetes, early diagnosis of the disease
and aggressive management of risk factors are
necessary to prevent or delay the development of
diabetic complications and the ensuing deteriora-
tion of HRQOL.
This study was funded by GlaxoSmithKline.
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